• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 461741 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1418908407 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1418908407 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of AMAG Pharmaceuticals Rise to a New 52-Week High

Published on Mon, 03/18/2013 - 14:10
By Peter Chu

AMAG Pharmaceuticals (NASDAQ:AMAG) traded today at a new 52-week high of $21.73. So far today approximately 112,000 shares have been exchanged, as compared to an average 30-day volume of 72,000 shares.

AMAG Pharmaceuticals (NASDAQ:AMAG) defies analysts with a current price ($21.69) 21.6% above its average consensus price target of $17.00. The stock should discover initial support at its 50-day moving average (MA) of $16.70 and subsequent support at its 200-day MA of $15.82.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Over the past year, AMAG Pharmaceuticals has traded in a range of $12.43 to $21.73 and is now at $21.69, 74% above that low. In the last five trading sessions, the 50-day moving average (MA) has climbed 3.0% while the 200-day MA has risen 1.0%.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Short-term Underperformance Detected in ...

Analysis was conducted on the Restaurants industry to measure relative performance to f ...

BioDelivery Sciences has the Best Relati...

We looked at the Life Sciences Tools & Services industry and measured relative performa ...

Shares of Associated Estates Realty Unde...

Below are five companies in the Residential REITs industry that underperformed yesterda ...

CNO Financial is Among the Companies in ...

Here are the top 5 stocks in the Life & Health Insurance industry ranked by performance ...

Shares of Platinum Underwriters Holdings...

Here are 5 stocks in the Reinsurance industry ranked by performance. We compiled the t ...

Shares of MAXIMUS Rank the Highest in Te...

We looked at the IT Consulting & Other Services industry and measured relative performa ...

Shares of Cullen/Frost Bankers Underperf...

Below are five companies in the Regional Banks industry that underperformed yesterday o ...

Evercore Partners is Among the Companies...

Below are the top five companies in the Investment Banking & Brokerage industry as meas ...